title: Apo E4/3-rich remnant lipoproteins and platelet aggregation: a case report.
authors.forename: A R
authors.initials: AR
authors.lastname: Saniabadi
authors.forename: S
authors.initials: S
authors.lastname: Takeich
authors.forename: N
authors.initials: N
authors.lastname: Yukawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nakajima
authors.forename: K
authors.initials: K
authors.lastname: Umemura
authors.forename: M
authors.initials: M
authors.lastname: Nakashima
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000378:metabolism; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000097:blood* / Q000235:genetics / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000235:genetics; D000077407:Cilostazol; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D006579:Heterozygote; D006801:Humans; D008074:Lipoproteins / Q000097:blood* / Q000302:isolation & purification / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D012307:Risk Factors; D013777:Tetrazoles / Q000494:pharmacology
chemical_list: D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D008074:Lipoproteins; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D015762:2-Chloroadenosine; D000244:Adenosine Diphosphate; D000077407:Cilostazol; D001241:Aspirin